作者
Stein-Erik Gullaksen, Jørn Skavland, Krzysztof Warzocha, Sonia Gavasso, Vinko Tosevski, Noortje Thielen, Jaroslava Voglova, Augustin Ferrant, Werner Linkesch, Josef Thaler, Alois Lang, Jesper Stentoft, Tobias Gedde-Dahl, Henrik Hjorth-Hansen, Waleed Majeed, Gregor Verhoef, Andrzej Hellmann, Georgi G Mihaylov, Claudia Dumrese, Frank Giles, Andreas Hochhaus, Sieghart Sopper, Leif Stenke, Boris Labar, Jeroen Janssen, Kimmo Porkka, Gert J Ossenkoppele, Satu Mustjoki, Dominik Wolf, Bjorn T Gjertsen
发表日期
2015/12/3
期刊
Blood
卷号
126
期号
23
页码范围
4022
出版商
Content Repository Only!
简介
Earlier evaluation of therapy effect in patients with CML would assist in optimal use of available tyrosine kinase inhibitors (TKI). Single cell analysis by mass cytometry has enabled the quantification of up to 46 antibody epitopes, making it ideally suited for exhaustive immunophenotyping of the haematological hierarchy, and evaluation of associated dynamic signal transduction events, in a clinical setting. By integrating time resolved single cell signalling data with clinical parameters, we searched for prognostic and efficacy-response mass cytometry biomarkers within a month of TKI therapy. We report data from experiments used to validate the custom panels of antibodies, highlighting the power of mass cytometry in the analysis of primary patient material obtained on clinical studies.
Peripheral Blood (PB) samples were collected before, 3 hours, 7 days and 28 days, after start of nilotinib (300 mg BID) treatment in a …
学术搜索中的文章
SE Gullaksen, J Skavland, K Warzocha, S Gavasso… - Blood, 2015